ProCE Banner Activity

KRYSTAL-1: Phase Ib Report of Adagrasib Activity in Patients With KRAS G12C–Mutated NSCLC and Active, Untreated CNS Metastases

Slideset Download
Conference Coverage
In this small cohort of patients with KRAS G12C–mutant NSCLC and active, untreated CNS metastases, adagrasib shows encouraging clinical activity and safety, yielding objective intracranial responses in a third of patients.

Released: June 13, 2022

Expiration: June 12, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab